Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.
about
HIV infection, aging, and immune function: implications for cancer risk and preventionSoluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeA plasma biomarker signature of immune activation in HIV patients on antiretroviral therapyDynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineReduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.Empiric deworming and CD4 count recovery in HIV-infected Ugandans initiating antiretroviral therapy.Residual immune dysregulation syndrome in treated HIV infection.Dynamics of regulatory T-cells during pregnancy: effect of HIV infection and correlations with other immune parameters.Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4.Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesisBiomarkers of immune dysfunction in HIV.Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotypePredictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patientsAssociation of Toll-like receptor polymorphisms with HIV status in North AmericansInflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in ZambiaHigher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or deathIdentification of three immunologic correlates for HIV type 1 pathogenesis in youthResumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trialDistinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers.Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infectionRosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.Multisite comparison of high-sensitivity multiplex cytokine assays.Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation.Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients.Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyHIV pathogenesis: the host.HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease.Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction.Associations of Circulating Soluble Tumor Necrosis Factor-α Receptors 1 and 2 with Interleukin-6 Levels in an Aging Cohort of Injection Drug Users with or at High Risk for HIV InfectionT cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs.Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV.
P2860
Q27004165-8C73883D-EB89-4717-A454-5B349337DA34Q27690715-62730642-2CC0-4D9A-A1C2-59F6CAFDE23CQ28088557-C96C5FC6-A21B-4887-8D06-4E251B8AABFEQ28480936-0B4A53E6-3D89-4CE8-A46F-0BCA08CF827DQ31146636-02E3A280-84E0-46E4-93AB-E1DE18344E9FQ31152445-BD0534FF-BA71-410E-AC52-1A4EDB1D3ACFQ33889154-4F3ABDFD-16C7-44BD-8DE1-3F54DAF4DF86Q33897898-7FFC9906-F970-4F79-84E1-07BBF6C896ABQ34016057-80702DF5-8870-4AA9-A232-DEEFBE6F1D5CQ34020121-8793C534-0060-4152-B1DE-E128D15F7A08Q34091313-8C1CF6C8-8F52-4F6D-996F-F6E3A9C6AE3AQ34202331-C5584B0B-1A36-49C8-8839-C77F30386DFFQ34229695-C0ECC082-6E79-47DA-B806-C131D81ED686Q34315572-48A456DA-2870-4F98-8323-4AF815EDD65BQ34387349-2AB938E4-F1DA-4879-9255-A78370EEF2DFQ34494208-B70B9D3E-2E3F-4B63-9802-910A26302105Q34505245-982F628E-A90F-4A90-ABB2-306603E2DAFCQ34546742-7593EBBC-2C04-49F4-9BF3-BEAD7904A722Q34627162-F5BE878F-4D15-432D-B71C-07D1C55109B3Q34634839-7B25F107-7427-452A-A877-D749EDEE1A2BQ34642208-FDF0D1D7-08A0-4C3D-A197-7FE4CA2C6B5FQ34796153-EE4CB03B-B386-421A-8294-7FF2CD59F620Q34812071-6581F3E1-FE21-4308-97A9-FC8811AB31A3Q34980769-39BA27AE-25ED-42E3-AD81-8A8B1CE90DC1Q34988273-0AF901A0-2801-4B85-95EE-DAC1648FEBF2Q35003524-BA4652BE-19D2-4F2E-8DC8-94B88A00069AQ35006056-0F1C9CBC-84DE-4140-9BE9-B955BC543325Q35023537-693DD529-FCD9-4CB0-9256-B5790ABDDC03Q35078598-818F96EB-CE52-4B88-B129-BB34C42D36E7Q35102167-5E360406-BAB8-4AE7-9BA2-04F247183A35Q35138815-B16CD867-F01B-4250-AAB5-22B102E4EC9DQ35655728-FE965CD9-7E86-4B79-AA25-993A10B52DD7Q35873402-68FA855E-909F-4E0C-872C-2EB95CE76E8FQ36068935-7E26B3B6-02DA-424F-8014-4B36ADD2FF1FQ36186538-EED4C340-DB88-4FF5-AE46-415C68C0CB26Q36279270-18ADD898-B9D7-4561-8B1C-9B5D58B7C9F5Q36291721-0E2AD25D-497F-40F3-B4E5-FA8924DE20F8Q36330047-7F15AEEE-6162-42BD-B9EB-11F7C03D0FE9Q36359499-88E96EC7-E16E-431E-901E-C8FF47D76587Q36377944-326C9460-B34B-4DC9-ADE3-59D079192C4D
P2860
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pretreatment levels of soluble ...... active antiretroviral therapy.
@ast
Pretreatment levels of soluble ...... active antiretroviral therapy.
@en
type
label
Pretreatment levels of soluble ...... active antiretroviral therapy.
@ast
Pretreatment levels of soluble ...... active antiretroviral therapy.
@en
prefLabel
Pretreatment levels of soluble ...... active antiretroviral therapy.
@ast
Pretreatment levels of soluble ...... active antiretroviral therapy.
@en
P2093
P2860
P356
P1476
Pretreatment levels of soluble ...... active antiretroviral therapy.
@en
P2093
Alan Landay
Gregory K Robbins
Michael M Lederman
Rajesh T Gandhi
Rhoderick N Machekano
Richard B Pollard
Robert C Kalayjian
P2860
P304
P356
10.1086/652750
P407
P577
2010-06-01T00:00:00Z